Did Phathom Pharmaceuticals’ 62% Drop Catch You Out? What Investors Missed

Phathom Pharmaceuticals spent 2026 releasing upbeat headlines, from a sharply smaller Q2 loss to fresh cost effectiveness data for VOQUEZNA at the ACG meeting. For Phathom Pharmaceuticals shareholders, the loss from the start of the year was 62.2%, including dividends. If you had put money in on 1 January, that gap between improving financial metrics and a deep capital drawdown is hard to ignore. Did the business story really change, or did expectations change?

Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.

Phathom Pharmaceuticals is not the only name tied to this theme. Zero in on 34 healthcare AI stocks and compare how each one is priced.

The Two Stories Investors Had To Weigh On Phathom Pharmaceuticals

The shares cost US$16.59 at the start of the period, and anyone looking at Phathom Pharmaceuticals then had to choose between two very different stories about where the value sat.

On the optimistic side, the bullish narrative put fair value at US$21.38, built on the idea that revenue could climb 75.1% a year and profit margins could move from a deep loss to 25.4% within three years.

The bearish view pointed to a fair value of US$12, assuming 60.4% annual revenue growth but warning that heavy reliance on a narrow gastrointestinal pipeline left future earnings exposed to concentration risk.

What The Results Changed For Phathom Pharmaceuticals

The clearest update came from Q2 2026, when Phathom Pharmaceuticals reported revenue of US$74.274 million and a net loss of US$17.582 million. Net margin improved to a 23.7% loss compared with a 191.9% loss a year earlier, which supported the optimistic case on efficiency but still left profitability unproven. The data therefore cut both ways.

The main assumption investors needed to track was the path to positive earnings. For a similar company, you would want to compare any stated profitability timeline with reported net margin and absolute profit every quarter.

What Phathom Pharmaceuticals’ Price Drop Now Asks You To Believe

Phathom Pharmaceuticals now trades at US$5.94 from the start of the year, and the selected Narrative’s Fair Value sits above the current price. That view leans on VOQUEZNA’s prescription base, the Q2 2026 shift to positive operating profit, and cash from operations.

For the fall to hint at opportunity rather than warning, a buyer today would need to believe VOQUEZNA can keep converting specialist PPI scripts despite payer friction and a highly generic GERD market.

"The current valuation implies the market is assigning limited credit to VOQUEZNA’s prescription base of about 1.7 million cumulative fills, the progress toward positive operating profit and cash from operations in Q2 2026, and the potential revenue contribution from planned indication and dosing expansions."

One Narrative disagrees with today's price. → See where this Narrative says Phathom Pharmaceuticals should trade

Find Your Own Contrarian Opportunity

The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.

• Company 1 - 35% below our estimate - converts a record advisory pipeline and recent senior hires into higher-fee transactions.
• Company 2 - 19% below our estimate - rides a surging datacenter build cycle as a swelling backlog reshapes visibility.
• Company 3 - 41% below our estimate - scales larger LED display projects while executing a margin plan tied to services.

Those are three of them. See every one of the 29 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com